Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TGTX |
---|---|---|
09:32 ET | 11065 | 23.45 |
09:34 ET | 5157 | 23.43 |
09:36 ET | 2815 | 23.435 |
09:38 ET | 12317 | 23.575 |
09:39 ET | 8291 | 23.605 |
09:41 ET | 9403 | 23.65 |
09:43 ET | 31758 | 23.8 |
09:45 ET | 6719 | 23.836 |
09:48 ET | 9961 | 23.824 |
09:50 ET | 8900 | 23.7599 |
09:52 ET | 5866 | 23.69 |
09:54 ET | 5713 | 23.71 |
09:56 ET | 3728 | 23.77 |
09:57 ET | 1800 | 23.64 |
09:59 ET | 1804 | 23.705 |
10:01 ET | 6119 | 23.6148 |
10:03 ET | 1477 | 23.63 |
10:06 ET | 5927 | 23.6136 |
10:08 ET | 10279 | 23.76 |
10:10 ET | 10350 | 23.79 |
10:12 ET | 13868 | 23.79 |
10:14 ET | 4905 | 23.71 |
10:15 ET | 6638 | 23.78 |
10:17 ET | 21604 | 23.8001 |
10:19 ET | 5741 | 23.79 |
10:21 ET | 9616 | 23.83 |
10:24 ET | 24574 | 23.825 |
10:26 ET | 4917 | 23.835 |
10:28 ET | 4718 | 23.82 |
10:30 ET | 29980 | 23.8625 |
10:32 ET | 10633 | 23.85 |
10:33 ET | 4325 | 23.83 |
10:35 ET | 5896 | 23.82 |
10:37 ET | 11991 | 23.84 |
10:39 ET | 11793 | 23.87 |
10:42 ET | 8236 | 23.82 |
10:44 ET | 9296 | 23.845 |
10:46 ET | 26141 | 23.9399 |
10:48 ET | 27548 | 23.98 |
10:50 ET | 23002 | 24.01 |
10:51 ET | 6853 | 24 |
10:53 ET | 3651 | 23.98 |
10:55 ET | 7448 | 23.98 |
10:57 ET | 4000 | 23.91 |
11:00 ET | 4840 | 23.94 |
11:02 ET | 3651 | 23.89 |
11:04 ET | 3200 | 23.9 |
11:06 ET | 8301 | 23.88 |
11:08 ET | 3700 | 23.91 |
11:09 ET | 3801 | 23.91 |
11:11 ET | 800 | 23.92 |
11:13 ET | 5759 | 23.88 |
11:15 ET | 1950 | 23.89 |
11:18 ET | 2826 | 23.93 |
11:20 ET | 4731 | 23.945 |
11:22 ET | 4729 | 23.95 |
11:24 ET | 3410 | 23.895 |
11:26 ET | 1812 | 23.92 |
11:27 ET | 1854 | 23.89 |
11:29 ET | 1661 | 23.92 |
11:31 ET | 854 | 23.93 |
11:33 ET | 9421 | 23.94 |
11:36 ET | 4229 | 23.88 |
11:38 ET | 2696 | 23.88 |
11:40 ET | 1644 | 23.85 |
11:42 ET | 1385 | 23.835 |
11:44 ET | 1820 | 23.835 |
11:45 ET | 7284 | 23.856 |
11:47 ET | 1300 | 23.86 |
11:49 ET | 4817 | 23.89 |
11:51 ET | 1100 | 23.88 |
11:54 ET | 8175 | 23.88 |
11:56 ET | 1445 | 23.93 |
11:58 ET | 5635 | 23.95 |
12:00 ET | 21415 | 23.955 |
12:02 ET | 3770 | 23.91 |
12:03 ET | 6945 | 23.95 |
12:05 ET | 3100 | 23.91 |
12:07 ET | 1528 | 23.91 |
12:09 ET | 4621 | 23.9 |
12:12 ET | 3250 | 23.88 |
12:14 ET | 2545 | 23.88 |
12:16 ET | 5964 | 23.83 |
12:18 ET | 2100 | 23.85 |
12:20 ET | 2300 | 23.85 |
12:21 ET | 906 | 23.89 |
12:23 ET | 1751 | 23.8726 |
12:25 ET | 2493 | 23.86 |
12:27 ET | 600 | 23.85 |
12:30 ET | 7407 | 23.89 |
12:32 ET | 1100 | 23.86 |
12:34 ET | 900 | 23.86 |
12:36 ET | 1108 | 23.86 |
12:38 ET | 2402 | 23.8841 |
12:39 ET | 3059 | 23.87 |
12:41 ET | 500 | 23.87 |
12:43 ET | 2900 | 23.85 |
12:45 ET | 1800 | 23.84 |
12:48 ET | 200 | 23.83 |
12:50 ET | 404 | 23.82 |
12:52 ET | 500 | 23.81 |
12:54 ET | 300 | 23.8 |
12:56 ET | 2294 | 23.81 |
12:57 ET | 7736 | 23.74 |
12:59 ET | 4638 | 23.765 |
01:01 ET | 875 | 23.77 |
01:03 ET | 1012 | 23.8 |
01:06 ET | 1942 | 23.8 |
01:08 ET | 2250 | 23.79 |
01:10 ET | 3210 | 23.74 |
01:12 ET | 900 | 23.76 |
01:14 ET | 1409 | 23.78 |
01:15 ET | 1900 | 23.8 |
01:17 ET | 4226 | 23.82 |
01:19 ET | 700 | 23.81 |
01:21 ET | 4003 | 23.86 |
01:24 ET | 1200 | 23.86 |
01:26 ET | 2013 | 23.89 |
01:28 ET | 4382 | 23.8799 |
01:30 ET | 2155 | 23.87 |
01:32 ET | 2455 | 23.88 |
01:33 ET | 2856 | 23.8301 |
01:35 ET | 1800 | 23.83 |
01:37 ET | 874 | 23.83 |
01:39 ET | 13430 | 23.77 |
01:42 ET | 1638 | 23.765 |
01:44 ET | 1721 | 23.765 |
01:46 ET | 3369 | 23.78 |
01:48 ET | 2520 | 23.78 |
01:50 ET | 5098 | 23.815 |
01:51 ET | 905 | 23.82 |
01:53 ET | 2501 | 23.825 |
01:55 ET | 619 | 23.83 |
01:57 ET | 2465 | 23.83 |
02:00 ET | 1233 | 23.83 |
02:02 ET | 1787 | 23.845 |
02:04 ET | 1103 | 23.83 |
02:06 ET | 1750 | 23.845 |
02:08 ET | 6969 | 23.7925 |
02:09 ET | 2988 | 23.79 |
02:11 ET | 2668 | 23.84 |
02:13 ET | 1328 | 23.825 |
02:15 ET | 1602 | 23.85 |
02:18 ET | 1200 | 23.85 |
02:20 ET | 3170 | 23.82 |
02:22 ET | 2476 | 23.855 |
02:24 ET | 29661 | 23.88 |
02:26 ET | 2000 | 23.86 |
02:27 ET | 2500 | 23.82 |
02:29 ET | 2920 | 23.82 |
02:31 ET | 8820 | 23.77 |
02:33 ET | 14529 | 23.82 |
02:36 ET | 3232 | 23.83 |
02:38 ET | 2500 | 23.82 |
02:40 ET | 3272 | 23.82 |
02:42 ET | 1050 | 23.83 |
02:44 ET | 900 | 23.84 |
02:45 ET | 1100 | 23.84 |
02:47 ET | 2900 | 23.855 |
02:49 ET | 850 | 23.86 |
02:51 ET | 3600 | 23.8808 |
02:54 ET | 7498 | 23.885 |
02:56 ET | 2455 | 23.89 |
02:58 ET | 12577 | 23.93 |
03:00 ET | 14989 | 23.935 |
03:02 ET | 4777 | 23.91 |
03:03 ET | 5928 | 23.89 |
03:05 ET | 9100 | 23.898 |
03:07 ET | 28510 | 23.895 |
03:09 ET | 2658 | 23.895 |
03:12 ET | 6975 | 23.86 |
03:14 ET | 1057 | 23.87 |
03:16 ET | 2078 | 23.87 |
03:18 ET | 1118 | 23.84 |
03:20 ET | 6942 | 23.85 |
03:21 ET | 6124 | 23.84 |
03:23 ET | 4711 | 23.85 |
03:25 ET | 3467 | 23.83 |
03:27 ET | 4616 | 23.8101 |
03:30 ET | 2030 | 23.82 |
03:32 ET | 9862 | 23.84 |
03:34 ET | 6070 | 23.83 |
03:36 ET | 8728 | 23.845 |
03:38 ET | 5402 | 23.82 |
03:39 ET | 10025 | 23.8291 |
03:41 ET | 3463 | 23.815 |
03:43 ET | 3222 | 23.815 |
03:45 ET | 5407 | 23.81 |
03:48 ET | 7020 | 23.79 |
03:50 ET | 4875 | 23.76 |
03:52 ET | 16815 | 23.79 |
03:54 ET | 4931 | 23.82 |
03:56 ET | 31979 | 23.825 |
03:57 ET | 23206 | 23.8403 |
03:59 ET | 287327 | 23.83 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
TG Therapeutics Inc | 3.7B | 39.7x | --- |
ADMA Biologics Inc | 4.2B | 137.9x | --- |
Twist Bioscience Corp | 2.8B | -12.2x | --- |
Arrowhead Pharmaceuticals Inc | 2.7B | -4.2x | --- |
Axsome Therapeutics Inc | 4.5B | -13.8x | --- |
Arcellx Inc | 4.1B | -78.7x | --- |
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.7B |
---|---|
Revenue (TTM) | $346.7M |
Shares Outstanding | 154.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.21 |
EPS | $0.60 |
Book Value | $1.06 |
P/E Ratio | 39.7x |
Price/Sales (TTM) | 10.6 |
Price/Cash Flow (TTM) | 38.3x |
Operating Margin | 29.37% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.